Hmdb loader
Survey
You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
Version5.0
StatusDetected but not Quantified
Creation Date2012-09-06 15:16:49 UTC
Update Date2022-03-07 02:51:35 UTC
HMDB IDHMDB0014367
Secondary Accession Numbers
  • HMDB14367
Metabolite Identification
Common NameGlimepiride
DescriptionGlimepiride is only found in individuals that have used or taken this drug. It is the first III generation sulphonyl urea it is a very potent sulphonyl urea with long duration of action.The mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glimepiride likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.
Structure
Data?1582753170
Synonyms
ValueSource
AmarylKegg
GlimepiridHMDB
GlimepiridaHMDB
GlimepiridumHMDB
GlimeprideHMDB
1-(4-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrrolinecarboxamido)ethyl)phenylsulfonyl)-3-(4-methylcyclohexyl)ureaHMDB
Aventis pharma brand OF glimepirideHMDB
Hoechst brand OF glimepirideHMDB
Aventis behring brand OF glimepirideHMDB
RonameHMDB
AmarelHMDB
Aventis brand OF glimepirideHMDB
GlymepirideHMDB
HOE 490HMDB
HOE-490HMDB
Lacer brand OF glimepirideHMDB
3-Ethyl-4-methyl-N-{2-[4-({[(4-methylcyclohexyl)-C-hydroxycarbonimidoyl]amino}sulfonyl)phenyl]ethyl}-2-oxo-2,5-dihydro-1H-pyrrole-1-carboximidateGenerator
3-Ethyl-4-methyl-N-{2-[4-({[(4-methylcyclohexyl)-C-hydroxycarbonimidoyl]amino}sulphonyl)phenyl]ethyl}-2-oxo-2,5-dihydro-1H-pyrrole-1-carboximidateGenerator
3-Ethyl-4-methyl-N-{2-[4-({[(4-methylcyclohexyl)-C-hydroxycarbonimidoyl]amino}sulphonyl)phenyl]ethyl}-2-oxo-2,5-dihydro-1H-pyrrole-1-carboximidic acidGenerator
Chemical FormulaC24H34N4O5S
Average Molecular Weight490.616
Monoisotopic Molecular Weight490.224990908
IUPAC Name3-ethyl-4-methyl-N-{2-[4-({[(4-methylcyclohexyl)carbamoyl]amino}sulfonyl)phenyl]ethyl}-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
Traditional Nameglimepiride
CAS Registry Number93479-97-1
SMILES
CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC2CCC(C)CC2)C1=O
InChI Identifier
InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)
InChI KeyWIGIZIANZCJQQY-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Benzenesulfonamide
  • Benzenesulfonyl group
  • N-acyl urea
  • Sulfonylurea
  • Ureide
  • Pyrroline
  • Organic sulfonic acid or derivatives
  • Organosulfonic acid or derivatives
  • Sulfonyl
  • Aminosulfonyl compound
  • Isourea
  • Carboximidic acid derivative
  • Carboxylic acid derivative
  • Azacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organic oxide
  • Hydrocarbon derivative
  • Carbonyl group
  • Organic nitrogen compound
  • Organic oxygen compound
  • Organopnictogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting Point207 °CNot Available
Boiling PointNot AvailableNot Available
Water Solubility0.038 g/LNot Available
LogP3.5Not Available
Experimental Chromatographic Properties

Experimental Collision Cross Sections

Adduct TypeData SourceCCS Value (Å2)Reference
[M+H]+CBM216.630932474
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.038 g/LALOGPS
logP2.82ALOGPS
logP3.12ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)4.32ChemAxon
pKa (Strongest Basic)-3.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area124.68 ŲChemAxon
Rotatable Bond Count6ChemAxon
Refractivity129.8 m³·mol⁻¹ChemAxon
Polarizability53.86 ųChemAxon
Number of Rings3ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+214.27531661259
DarkChem[M-H]-207.2131661259
DeepCCS[M+H]+215.39630932474
DeepCCS[M-H]-213.00130932474
DeepCCS[M-2H]-246.04130932474
DeepCCS[M+Na]+221.30930932474
AllCCS[M+H]+216.332859911
AllCCS[M+H-H2O]+214.632859911
AllCCS[M+NH4]+217.832859911
AllCCS[M+Na]+218.232859911
AllCCS[M-H]-203.232859911
AllCCS[M+Na-2H]-204.932859911
AllCCS[M+HCOO]-206.932859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
GlimepirideCCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC2CCC(C)CC2)C1=O5535.1Standard polar33892256
GlimepirideCCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC2CCC(C)CC2)C1=O3582.2Standard non polar33892256
GlimepirideCCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC2CCC(C)CC2)C1=O4115.0Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Glimepiride,1TMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)NC(=O)NC3CCC(C)CC3)C=C2)[Si](C)(C)C)C1=O4008.4Semi standard non polar33892256
Glimepiride,1TMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)NC(=O)NC3CCC(C)CC3)C=C2)[Si](C)(C)C)C1=O3670.4Standard non polar33892256
Glimepiride,1TMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)NC(=O)NC3CCC(C)CC3)C=C2)[Si](C)(C)C)C1=O5406.2Standard polar33892256
Glimepiride,1TMS,isomer #2CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)N(C(=O)NC3CCC(C)CC3)[Si](C)(C)C)C=C2)C1=O4039.5Semi standard non polar33892256
Glimepiride,1TMS,isomer #2CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)N(C(=O)NC3CCC(C)CC3)[Si](C)(C)C)C=C2)C1=O3675.5Standard non polar33892256
Glimepiride,1TMS,isomer #2CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)N(C(=O)NC3CCC(C)CC3)[Si](C)(C)C)C=C2)C1=O5425.6Standard polar33892256
Glimepiride,1TMS,isomer #3CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)NC(=O)N(C3CCC(C)CC3)[Si](C)(C)C)C=C2)C1=O4049.8Semi standard non polar33892256
Glimepiride,1TMS,isomer #3CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)NC(=O)N(C3CCC(C)CC3)[Si](C)(C)C)C=C2)C1=O3739.5Standard non polar33892256
Glimepiride,1TMS,isomer #3CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)NC(=O)N(C3CCC(C)CC3)[Si](C)(C)C)C=C2)C1=O5371.3Standard polar33892256
Glimepiride,2TMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)N(C(=O)NC3CCC(C)CC3)[Si](C)(C)C)C=C2)[Si](C)(C)C)C1=O3848.4Semi standard non polar33892256
Glimepiride,2TMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)N(C(=O)NC3CCC(C)CC3)[Si](C)(C)C)C=C2)[Si](C)(C)C)C1=O3816.1Standard non polar33892256
Glimepiride,2TMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)N(C(=O)NC3CCC(C)CC3)[Si](C)(C)C)C=C2)[Si](C)(C)C)C1=O5266.0Standard polar33892256
Glimepiride,2TMS,isomer #2CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)NC(=O)N(C3CCC(C)CC3)[Si](C)(C)C)C=C2)[Si](C)(C)C)C1=O3867.6Semi standard non polar33892256
Glimepiride,2TMS,isomer #2CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)NC(=O)N(C3CCC(C)CC3)[Si](C)(C)C)C=C2)[Si](C)(C)C)C1=O3873.4Standard non polar33892256
Glimepiride,2TMS,isomer #2CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)NC(=O)N(C3CCC(C)CC3)[Si](C)(C)C)C=C2)[Si](C)(C)C)C1=O5143.7Standard polar33892256
Glimepiride,2TMS,isomer #3CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)N(C(=O)N(C3CCC(C)CC3)[Si](C)(C)C)[Si](C)(C)C)C=C2)C1=O3880.8Semi standard non polar33892256
Glimepiride,2TMS,isomer #3CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)N(C(=O)N(C3CCC(C)CC3)[Si](C)(C)C)[Si](C)(C)C)C=C2)C1=O3922.3Standard non polar33892256
Glimepiride,2TMS,isomer #3CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)N(C(=O)N(C3CCC(C)CC3)[Si](C)(C)C)[Si](C)(C)C)C=C2)C1=O5136.9Standard polar33892256
Glimepiride,3TMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)N(C(=O)N(C3CCC(C)CC3)[Si](C)(C)C)[Si](C)(C)C)C=C2)[Si](C)(C)C)C1=O3769.9Semi standard non polar33892256
Glimepiride,3TMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)N(C(=O)N(C3CCC(C)CC3)[Si](C)(C)C)[Si](C)(C)C)C=C2)[Si](C)(C)C)C1=O4065.8Standard non polar33892256
Glimepiride,3TMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)N(C(=O)N(C3CCC(C)CC3)[Si](C)(C)C)[Si](C)(C)C)C=C2)[Si](C)(C)C)C1=O4913.8Standard polar33892256
Glimepiride,1TBDMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)NC(=O)NC3CCC(C)CC3)C=C2)[Si](C)(C)C(C)(C)C)C1=O4216.9Semi standard non polar33892256
Glimepiride,1TBDMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)NC(=O)NC3CCC(C)CC3)C=C2)[Si](C)(C)C(C)(C)C)C1=O3869.0Standard non polar33892256
Glimepiride,1TBDMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)NC(=O)NC3CCC(C)CC3)C=C2)[Si](C)(C)C(C)(C)C)C1=O5448.3Standard polar33892256
Glimepiride,1TBDMS,isomer #2CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)N(C(=O)NC3CCC(C)CC3)[Si](C)(C)C(C)(C)C)C=C2)C1=O4262.6Semi standard non polar33892256
Glimepiride,1TBDMS,isomer #2CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)N(C(=O)NC3CCC(C)CC3)[Si](C)(C)C(C)(C)C)C=C2)C1=O3877.2Standard non polar33892256
Glimepiride,1TBDMS,isomer #2CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)N(C(=O)NC3CCC(C)CC3)[Si](C)(C)C(C)(C)C)C=C2)C1=O5447.2Standard polar33892256
Glimepiride,1TBDMS,isomer #3CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)NC(=O)N(C3CCC(C)CC3)[Si](C)(C)C(C)(C)C)C=C2)C1=O4292.4Semi standard non polar33892256
Glimepiride,1TBDMS,isomer #3CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)NC(=O)N(C3CCC(C)CC3)[Si](C)(C)C(C)(C)C)C=C2)C1=O3973.6Standard non polar33892256
Glimepiride,1TBDMS,isomer #3CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)NC(=O)N(C3CCC(C)CC3)[Si](C)(C)C(C)(C)C)C=C2)C1=O5377.1Standard polar33892256
Glimepiride,2TBDMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)N(C(=O)NC3CCC(C)CC3)[Si](C)(C)C(C)(C)C)C=C2)[Si](C)(C)C(C)(C)C)C1=O4286.7Semi standard non polar33892256
Glimepiride,2TBDMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)N(C(=O)NC3CCC(C)CC3)[Si](C)(C)C(C)(C)C)C=C2)[Si](C)(C)C(C)(C)C)C1=O4217.5Standard non polar33892256
Glimepiride,2TBDMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)N(C(=O)NC3CCC(C)CC3)[Si](C)(C)C(C)(C)C)C=C2)[Si](C)(C)C(C)(C)C)C1=O5268.1Standard polar33892256
Glimepiride,2TBDMS,isomer #2CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)NC(=O)N(C3CCC(C)CC3)[Si](C)(C)C(C)(C)C)C=C2)[Si](C)(C)C(C)(C)C)C1=O4295.2Semi standard non polar33892256
Glimepiride,2TBDMS,isomer #2CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)NC(=O)N(C3CCC(C)CC3)[Si](C)(C)C(C)(C)C)C=C2)[Si](C)(C)C(C)(C)C)C1=O4291.9Standard non polar33892256
Glimepiride,2TBDMS,isomer #2CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)NC(=O)N(C3CCC(C)CC3)[Si](C)(C)C(C)(C)C)C=C2)[Si](C)(C)C(C)(C)C)C1=O5140.8Standard polar33892256
Glimepiride,2TBDMS,isomer #3CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)N(C(=O)N(C3CCC(C)CC3)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C2)C1=O4360.3Semi standard non polar33892256
Glimepiride,2TBDMS,isomer #3CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)N(C(=O)N(C3CCC(C)CC3)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C2)C1=O4369.7Standard non polar33892256
Glimepiride,2TBDMS,isomer #3CCC1=C(C)CN(C(=O)NCCC2=CC=C(S(=O)(=O)N(C(=O)N(C3CCC(C)CC3)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C2)C1=O5132.8Standard polar33892256
Glimepiride,3TBDMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)N(C(=O)N(C3CCC(C)CC3)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C2)[Si](C)(C)C(C)(C)C)C1=O4435.9Semi standard non polar33892256
Glimepiride,3TBDMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)N(C(=O)N(C3CCC(C)CC3)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C2)[Si](C)(C)C(C)(C)C)C1=O4703.2Standard non polar33892256
Glimepiride,3TBDMS,isomer #1CCC1=C(C)CN(C(=O)N(CCC2=CC=C(S(=O)(=O)N(C(=O)N(C3CCC(C)CC3)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C2)[Si](C)(C)C(C)(C)C)C1=O4945.2Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Glimepiride GC-MS (Non-derivatized) - 70eV, Positivesplash10-057r-8927300000-4b19465ae6452def91b62017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Glimepiride GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Glimepiride GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental LC-MS/MSLC-MS/MS Spectrum - Glimepiride LC-ESI-QFT , negative-QTOFsplash10-004i-0092300000-285644d8691c9bbbb3c12017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Glimepiride 20V, Negative-QTOFsplash10-0h09-0049400000-0631be1ca446334196492021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Glimepiride 30V, Negative-QTOFsplash10-004i-0093000000-b095deddf26c757a56db2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Glimepiride 40V, Negative-QTOFsplash10-004i-0090000000-2f31dbba814d4fc74d4b2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Glimepiride 10V, Negative-QTOFsplash10-000i-0000900000-ae14eaf56e7ba207ec2a2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Glimepiride 35V, Negative-QTOFsplash10-01ri-0059800000-900738971106854d79832021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Glimepiride LC-ESI-QFT , positive-QTOFsplash10-0fb9-0904000000-d6963d3854c74729a0022017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Glimepiride 20V, Positive-QTOFsplash10-0h09-0049400000-e3bb982b8c808c02a9952021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Glimepiride 20V, Positive-QTOFsplash10-0udi-0109000000-caa2d4614781791278a32021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Glimepiride 30V, Positive-QTOFsplash10-004i-0905000000-ccc3ed478df3f4bc06b22021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Glimepiride 10V, Positive-QTOFsplash10-0udi-0009400000-c2399edbd79ea939be912021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Glimepiride 35V, Positive-QTOFsplash10-0fb9-0906000000-286016fc46bf76e1fa892021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Glimepiride 40V, Positive-QTOFsplash10-004i-0900000000-54dca52a9e8453ef5a7e2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Glimepiride 50V, Positive-QTOFsplash10-004i-0900000000-7b7087bc285c4563d7422021-09-20HMDB team, MONAView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Glimepiride 10V, Negative-QTOFsplash10-000i-2606900000-d7aa8b2150735c01ffb82017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Glimepiride 20V, Negative-QTOFsplash10-0fmi-1927000000-f832ef63dab58a6608322017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Glimepiride 40V, Negative-QTOFsplash10-0229-5900000000-9d6f732c03d4d2775b4c2017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Glimepiride 10V, Negative-QTOFsplash10-000i-0001900000-0084efa26b4193acc57d2021-09-22Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Glimepiride 20V, Negative-QTOFsplash10-00di-4900000000-fa88a92f3e9f63b6d7942021-09-22Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Glimepiride 40V, Negative-QTOFsplash10-006w-9610000000-626a1442a6941d8e3bc12021-09-22Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Glimepiride 10V, Positive-QTOFsplash10-0udl-0907600000-4ad0adf1f2779efb32e42017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Glimepiride 20V, Positive-QTOFsplash10-0fb9-1901000000-2e64d2b8b6f32b2f8ca62017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Glimepiride 40V, Positive-QTOFsplash10-0690-8900000000-3dc90b58624dcd446c152017-09-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Glimepiride 10V, Positive-QTOFsplash10-0udi-0309200000-ca1536f76ae138ba22972021-09-23Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Glimepiride 20V, Positive-QTOFsplash10-0ufr-1934100000-e5415d3e1f6b86b7f26c2021-09-23Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothNormal details
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00222 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00222 details
UrineDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothNormal details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID3357
KEGG Compound IDC07669
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkGlimepiride
METLIN IDNot Available
PubChem Compound3476
PDB IDNot Available
ChEBI ID5383
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General ReferencesNot Available

Enzymes

General function:
Involved in monooxygenase activity
Specific function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan.
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular weight:
55627.365
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
General function:
Involved in inward rectifier potassium channel activity
Specific function:
In the kidney, probably plays a major role in potassium homeostasis. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. This channel is activated by internal ATP and can be blocked by external barium
Gene Name:
KCNJ1
Uniprot ID:
P48048
Molecular weight:
44794.6
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Proks P, Reimann F, Green N, Gribble F, Ashcroft F: Sulfonylurea stimulation of insulin secretion. Diabetes. 2002 Dec;51 Suppl 3:S368-76. [PubMed:12475777 ]
  4. Bataille D: [Molecular mechanisms of insulin secretion]. Diabetes Metab. 2002 Dec;28(6 Suppl):4S7-13. [PubMed:12703060 ]
General function:
Involved in inward rectifier potassium channel activity
Specific function:
This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium
Gene Name:
KCNJ11
Uniprot ID:
Q14654
Molecular weight:
43540.4
References
  1. Song DK, Ashcroft FM: Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J Pharmacol. 2001 May;133(1):193-9. [PubMed:11325810 ]
  2. Lawrence CL, Rainbow RD, Davies NW, Standen NB: Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal K(ATP) channels. Br J Pharmacol. 2002 Jul;136(5):746-52. [PubMed:12086984 ]
  3. Bataille D: [Molecular mechanisms of insulin secretion]. Diabetes Metab. 2002 Dec;28(6 Suppl):4S7-13. [PubMed:12703060 ]
General function:
Involved in ATP binding
Specific function:
Putative subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release
Gene Name:
ABCC8
Uniprot ID:
Q09428
Molecular weight:
177006.4
References
  1. Muller G, Hartz D, Punter J, Okonomopulos R, Kramer W: Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta. 1994 May 11;1191(2):267-77. [PubMed:8172912 ]
  2. Kramer W, Muller G, Geisen K: Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Horm Metab Res. 1996 Sep;28(9):464-8. [PubMed:8911984 ]
  3. Kramer W, Muller G, Girbig F, Gutjahr U, Kowalewski S, Hartz D, Summ HD: The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Diabetes Res Clin Pract. 1995 Aug;28 Suppl:S67-80. [PubMed:8529521 ]